MA32482B1 - Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin - Google Patents

Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin

Info

Publication number
MA32482B1
MA32482B1 MA33526A MA33526A MA32482B1 MA 32482 B1 MA32482 B1 MA 32482B1 MA 33526 A MA33526 A MA 33526A MA 33526 A MA33526 A MA 33526A MA 32482 B1 MA32482 B1 MA 32482B1
Authority
MA
Morocco
Prior art keywords
disease
hdac inhibitors
treat hodgkin
hodgkin
treat
Prior art date
Application number
MA33526A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32482B1 publication Critical patent/MA32482B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur l'utilisation d'un inhibiteur de hdac, notamment un inhibiteur de hdac représenté par la formule i : [i], dans laquelle les radicaux et les symboles ont les significations définies dans la description, pour la préparation d'un médicament destiné au traitement de la maladie de hodgkin.
MA33526A 2008-07-18 2011-01-14 Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin MA32482B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8180508P 2008-07-18 2008-07-18
PCT/US2009/050768 WO2010009280A1 (fr) 2008-07-18 2009-07-16 Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin

Publications (1)

Publication Number Publication Date
MA32482B1 true MA32482B1 (fr) 2011-07-03

Family

ID=41128203

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33526A MA32482B1 (fr) 2008-07-18 2011-01-14 Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin

Country Status (15)

Country Link
US (1) US20110118309A1 (fr)
EP (1) EP2306996A1 (fr)
JP (1) JP2011528662A (fr)
KR (1) KR20110031980A (fr)
CN (1) CN102099021A (fr)
AU (1) AU2009270886A1 (fr)
BR (1) BRPI0915927A2 (fr)
CA (1) CA2730738A1 (fr)
CL (1) CL2011000100A1 (fr)
IL (1) IL210489A0 (fr)
MA (1) MA32482B1 (fr)
MX (1) MX2011000719A (fr)
TW (1) TW201006470A (fr)
WO (1) WO2010009280A1 (fr)
ZA (1) ZA201100165B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (fr) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, méthodes, systèmes et/ou kits pour prévenir et/ou traiter des néoplasmes
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
AU2020379812A1 (en) * 2019-11-06 2022-03-31 Dana-Farber Cancer Institute, Inc. Selective dual histone deacetylase 6/8 (HDAC6/8) degraders and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2008002862A1 (fr) * 2006-06-26 2008-01-03 Novartis Ag Composés organiques
US8093220B2 (en) * 2006-12-04 2012-01-10 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite

Also Published As

Publication number Publication date
IL210489A0 (en) 2011-03-31
AU2009270886A1 (en) 2010-01-21
CN102099021A (zh) 2011-06-15
BRPI0915927A2 (pt) 2016-06-07
ZA201100165B (en) 2011-09-28
MX2011000719A (es) 2011-03-01
TW201006470A (en) 2010-02-16
CL2011000100A1 (es) 2011-07-01
WO2010009280A1 (fr) 2010-01-21
JP2011528662A (ja) 2011-11-24
US20110118309A1 (en) 2011-05-19
CA2730738A1 (fr) 2010-01-21
KR20110031980A (ko) 2011-03-29
EP2306996A1 (fr) 2011-04-13

Similar Documents

Publication Publication Date Title
MA32482B1 (fr) Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin
MA32171B1 (fr) Compose heterocyclique
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA31609B1 (fr) Imidazoles fusionnes pour le traitement du cancer
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA32965B1 (fr) Derives de sulfonamides
MA33492B1 (fr) Inhibiteurs de bace
MA33304B1 (fr) Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA33363B1 (fr) Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA33428B1 (fr) Agonistes du gpr119
EA201071100A1 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
MA31701B1 (fr) Depsipeptides cycliques
MA31873B1 (fr) Inhibiteurs de la peptide déformylase